YUCAIPA, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. , a medical device manufacturer, announced today that it has engaged an Oxyview(R) purchase agreement with Lincare Corporation for their more than 1000 locations in the United States.
Scott Sand, CEO and Chairman, states; “Lincare Corporation approved the US delivery of Oxyview(R) on January 16, 2008. Since Thursday last week we have sent out a fax-blast to all of the Lincare locations, and recently started receiving the first 6 purchase orders for 6 of their locations. Each order is for 10 or more units. We are expecting to deliver over a million units each year to Lincare patients. This would represent more than $8M in annual revenues for Ingen Technologies.”
Lincare Corporation has been synonymous with state-of-the-art oxygen systems since 1965. Their reputation for 24-hour, seven-days-a-week responsiveness, expert service representatives, and professional staff testifies to Lincare’s absolute commitment to provide the very best quality home respiratory service available. Lincare responds to the needs of every patient individually by providing the oxygen system most appropriate for his or her lifestyle. Oxygen concentrators, stationary and portable liquid oxygen systems, and high pressure cylinders are provided according to the physician’s prescription and with consideration for the activity level of each patient. Lincare regularly monitors how well each respiratory patient follows the prescribed course of treatment, ensuring compliance with liter flow and hours of use. Regularly monitoring patient compliance increases the likelihood that patients will receive the maximum benefit from the prescribed therapy.
“Ingen has been fortunate enough to attract the interest and distribution power of the world’s largest distributors of home oxygen supplies. Invacare Supply Group and Lincare Corporation represent over 95% of the US and World markets for respiratory care products. This affords the Company a channel to place Oxyview(R) and OxyAlert(R) with annual deliveries of over 20 million patients in the home setting and another 40 million patients in hospitals and skilled nursing facilities,” stated Thomas Neavitt, CFO.
About Ingen Technologies, Inc.
Ingen Technologies, Inc., a Georgia Corporation, is a medical device manufacturer, Certified through the Department of Health Services, and a publicly traded company trading under NASDAQ OTC: IGTG. The Company has been in business since 1999. Ingen received FDA clearance last year and offers products for the respiratory markets. The Oxyview(R) and OxyAlert(R) are proprietary products that increase accuracy of medical care and prevent unnecessary medical costs associated with today’s healthcare industry. Ingen owns a variety of intellectual biotech property including several US patent(s) and several Foreign Patent(s) either issued or pending in the US, Japan, European Communities and People’s Republic of China.
www.ingen-tech.comInfo@ingen-tech.com
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.
CONTACT: Scott R. Sand, C.E.O & Chairman of Ingen Technologies, Inc.,
+1-909-790-7180, fax, +1-909-795-6340, Info@ingen-tech.com
Web site: http://www.ingen-tech.com/
